Citations 0
From the Food and Drug Administration
October 3, 2001

Congestive Heart Failure Treatment

Author Affiliations

Not Available


Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001American Medical Association

Not Available

JAMA. 2001;286(13):1569. doi:10.1001/jama.286.13.1569-JFD10009-2-1

The FDA has approved nesiritide (Natrecor; Scios Inc, Sunnyvale, Calif) for initial intravenous treatment of patients with acutely decompensated congestive heart failure (ADCHF). The drug is a sterile, purified preparation containing the human B-type natriuretic peptide.

Nesiritide has been studied in 10 trials of patients with CHF, including the randomized Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial, which enrolled 489 patients requiring hospitalization for management of ADCHF with shortness of breath at rest.

First Page Preview View Large
First page PDF preview
First page PDF preview